Pacific trial

[nkmiami]

Imfinzi significantly reduces the risk of disease worsening or death in the Phase III PACIFIC trial for Stage III unresectable lung cancer

I had 2 patients on trial, both squamous IIIB that are 3 years out disease free.

---

Members don't see this ad.

 

[Chartreuse Wombat]

Imfinzi significantly reduces the risk of disease worsening or death in the Phase III PACIFIC trial for Stage III unresectable lung cancer

I had 2 patients on trial, both squamous IIIB that are 3 years out disease free.

Interesting that this appears on an industry website prior to publication.

 

[nkmiami]

will discourage opening up nrg/rtog chemo/xrt +/-opdivo if gets approved quickly

 

[medgator]

will discourage opening up nrg/rtog chemo/xrt +/-opdivo if gets approved quickly

Opdivo has been getting shafted by keytruda already... Interesting how this is playing out

 

[medgator]

FDA expands approval of Imfinzi to reduce the risk of non-small cell lung cancer progressing

It's already in the nccn guidelines, but without the FDA approval, it was hard to get anyone to give it. Now that won't be a problem, hopefully

 

[evilbooyaa]

They really gotta work on better names for these drugs.

Imfinzi? Sounds like "I'm Flimsy". The exact opposite of durvalumab (which reminds me of Duracell).

 

[medgator]

OS benefit

IMFINZI® (Durvalumab) Significantly Improves Overall Survival in the Phase III Pacific Trial for Unresectable Stage III Non-Small Cell Lung Cancer

 

[evilbooyaa]

Nice. Look forward to the paper.

 

[seper]

what kind of adverse events are you seeing with this?

 

[medgator]

what kind of adverse events are you seeing with this?

Have only had a few patients on it so far, seen one case of pneumonitis but it literally started the week after the first dose, over a month from chemo radiation. I figured it was the chemo rt but we held imfinzi and instituted high dose steroids which she is tapering off of now.

It only got fda approval a few months ago, before then it was more risky to give from a payment perspective I believe